ArticlePharmacological reports : PR2026
A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombined therapy with epidermal growth factor (EGF) and growth hormone-releasing peptide 6 (GHRP6) has demonstrated neuroprotective effects in models of global and focal brain ischemia. Clinical studies in ischemic stroke patients have confirmed the safety and preliminary efficacy of this combined treatment. This study aimed to elucidate the molecular mechanisms underlying the effects of EGF+GHRP6 co-administration.
methodsMale Wistar rats were subjected to endothelin-1 (ET-1)-induced middle cerebral artery (MCA) occlusion and randomly assigned to three experimental groups: EGF+GHRP6‑treated ischemic, vehicle‑treated ischemic, and sham-operated controls (n = 12 per group). Label-free quantitative proteomic analysis of the ischemic penumbra was performed at 3 and 24 h post-treatment. Functional enrichment and pathway analysis of differentially modulated proteins were performed using bioinformatics tools.
resultsProteomic profiling validated the ischemic model and revealed 40 and 223 proteins differentially modulated by EGF+GHRP6 at 3 and 24 h, respectively. Proteins involved in neurotransmitter transport were consistently overrepresented in the EGF+GHRP6-regulated proteome at both time points. At 24 h post-treatment, proteins associated with reactive oxygen species (ROS) detoxification, heat shock factor 1 (HSF1) activation, and negative regulation of cellular hypoxia response were significantly modulated. Additionally, anti-apoptotic and mitochondrial proteins were modulated in the ischemic penumbra, supporting the neuroprotective effects of EGF+GHRP6. Notably, proteins known to attenuate brain damage after stroke were up-regulated, while those promoting ischemic injury were down-regulated following the combined treatment.
conclusionsThese findings provide molecular evidence supporting the neuroprotective mechanism of action of EGF+GHRP6 co-administration and reinforce its potential as a therapeutic strategy for ischemic stroke.
Indexed as
Identifiers
42258095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.